FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1601583906> ?p ?o ?g. }

• W1601583906 endingPage "10115" @default.
• W1601583906 startingPage "10102" @default.
• W1601583906 abstract "// Xiaolei Li 1,2 , Junyan Tao 2,3 , Antonio Cigliano 4 , Marcella Sini 4 , Julien Calderaro 5,6 , Daniel Azoulay 7 , Chunmei Wang 2 , Yan Liu 1 , Lijie Jiang 2 , Katja Evert 4 , Maria I. Demartis 8 , Silvia Ribback 4 , Kirsten Utpatel 4 , Frank Dombrowski 4 , Matthias Evert 4 , Diego F. Calvisi 4,8 and Xin Chen 2,3 1 Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, P.R. China 2 Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, U.S.A 3 School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, P.R. China 4 Institute of Pathology, University Medicine of Greifswald, Greifswald, Germany 5 Department of Pathology, Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Henri Mondor, Créteil, France 6 Inserm, U1162, Génomique Fonctionnelle des Tumeurs Solides, Institut Universitaire d’Hematologie, Paris, France 7 Department of Digestive and Hepatobiliairy Surgery, Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Henri Mondor, Créteil, France 8 Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Correspondence to: Diego F. Calvisi, email: // Xin Chen, email: // Keywords : HCC, cholangiocarcinoma, liver tumor, PI3K, hippo Received : January 12, 2015 Accepted : February 13, 2015 Published : March 12, 2015 Abstract Activation of the PI3K and Yes-associated protein (Yap) signaling pathways has been independently reported in human hepatocellular carcinoma (HCC). However, the oncogenic interactions between these two cascades in hepatocarcinogenesis remain undetermined. To assess the consequences of the crosstalk between the PI3K and Yap pathways along liver carcinogenesis, we generated a mouse model characterized by combined overexpression of activated mutant forms of PIK3CA (PIK3CAH1047R) and Yap (YapS127A) in the mouse liver using hydrodynamic transfection (PIK3CA/Yap). In addition, suppression of PI3K and Yap pathways was conducted in human HCC and cholangiocarcinoma (CCA) cell lines. We found that concomitant activation of PI3K and Yap pathways triggered rapid liver tumor development in mice. Histologically, tumors were pure HCC, CCA, or mixed HCC/CCA. At the molecular level, PIK3CA/Yap tumors were characterized by activation of the mTORC1/2, ERK/MAPK, and Notch pathways. Simultaneous activation of PI3K and Yap pathways frequently occurred in human liver tumor specimens and their combined suppression was highly detrimental for the growth of HCC and CCA cell lines. In conclusion, our study demonstrates the oncogenic cooperation between PI3K and Yap pathways along liver carcinogenesis. The PIK3CA/Yap mouse represents an important preclinical liver tumor model for the development of novel therapeutics against this malignancy." @default.
• W1601583906 created "2016-06-24" @default.
• W1601583906 creator A5004361421 @default.
• W1601583906 creator A5021293751 @default.
• W1601583906 creator A5022582588 @default.
• W1601583906 creator A5028462736 @default.
• W1601583906 creator A5030639368 @default.
• W1601583906 creator A5038182004 @default.
• W1601583906 creator A5047006975 @default.
• W1601583906 creator A5053899400 @default.
• W1601583906 creator A5062134753 @default.
• W1601583906 creator A5066134441 @default.
• W1601583906 creator A5071263286 @default.
• W1601583906 creator A5075861619 @default.
• W1601583906 creator A5080612484 @default.
• W1601583906 creator A5080874150 @default.
• W1601583906 creator A5086116904 @default.
• W1601583906 creator A5088301199 @default.
• W1601583906 creator A5091038323 @default.
• W1601583906 date "2015-03-12" @default.
• W1601583906 modified "2023-09-30" @default.
• W1601583906 title "Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver" @default.
• W1601583906 cites W1968233108 @default.
• W1601583906 cites W1970820847 @default.
• W1601583906 cites W1971526515 @default.
• W1601583906 cites W1979368543 @default.
• W1601583906 cites W1980168406 @default.
• W1601583906 cites W1984621921 @default.
• W1601583906 cites W1986657600 @default.
• W1601583906 cites W1992294689 @default.
• W1601583906 cites W1994302891 @default.
• W1601583906 cites W2006778392 @default.
• W1601583906 cites W2008777301 @default.
• W1601583906 cites W2016211783 @default.
• W1601583906 cites W2018992554 @default.
• W1601583906 cites W2028593002 @default.
• W1601583906 cites W2028700227 @default.
• W1601583906 cites W2048453077 @default.
• W1601583906 cites W2054917860 @default.
• W1601583906 cites W2055254495 @default.
• W1601583906 cites W2060323466 @default.
• W1601583906 cites W2061965920 @default.
• W1601583906 cites W2073514136 @default.
• W1601583906 cites W2074648434 @default.
• W1601583906 cites W2087106096 @default.
• W1601583906 cites W2099709490 @default.
• W1601583906 cites W2100641053 @default.
• W1601583906 cites W2101538557 @default.
• W1601583906 cites W2102652088 @default.
• W1601583906 cites W2103496142 @default.
• W1601583906 cites W2103637700 @default.
• W1601583906 cites W2124059822 @default.
• W1601583906 cites W2129172946 @default.
• W1601583906 cites W2132052921 @default.
• W1601583906 cites W2132264180 @default.
• W1601583906 cites W2162242700 @default.
• W1601583906 cites W2167825227 @default.
• W1601583906 cites W2167978765 @default.
• W1601583906 doi "https://doi.org/10.18632/oncotarget.3546" @default.
• W1601583906 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4496343" @default.
• W1601583906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25826091" @default.
• W1601583906 hasPublicationYear "2015" @default.
• W1601583906 type Work @default.
• W1601583906 sameAs 1601583906 @default.
• W1601583906 citedByCount "57" @default.
• W1601583906 countsByYear W16015839062015 @default.
• W1601583906 countsByYear W16015839062016 @default.
• W1601583906 countsByYear W16015839062017 @default.
• W1601583906 countsByYear W16015839062018 @default.
• W1601583906 countsByYear W16015839062019 @default.
• W1601583906 countsByYear W16015839062020 @default.
• W1601583906 countsByYear W16015839062021 @default.
• W1601583906 countsByYear W16015839062022 @default.
• W1601583906 countsByYear W16015839062023 @default.
• W1601583906 crossrefType "journal-article" @default.
• W1601583906 hasAuthorship W1601583906A5004361421 @default.
• W1601583906 hasAuthorship W1601583906A5021293751 @default.
• W1601583906 hasAuthorship W1601583906A5022582588 @default.
• W1601583906 hasAuthorship W1601583906A5028462736 @default.
• W1601583906 hasAuthorship W1601583906A5030639368 @default.
• W1601583906 hasAuthorship W1601583906A5038182004 @default.
• W1601583906 hasAuthorship W1601583906A5047006975 @default.
• W1601583906 hasAuthorship W1601583906A5053899400 @default.
• W1601583906 hasAuthorship W1601583906A5062134753 @default.
• W1601583906 hasAuthorship W1601583906A5066134441 @default.
• W1601583906 hasAuthorship W1601583906A5071263286 @default.
• W1601583906 hasAuthorship W1601583906A5075861619 @default.
• W1601583906 hasAuthorship W1601583906A5080612484 @default.
• W1601583906 hasAuthorship W1601583906A5080874150 @default.
• W1601583906 hasAuthorship W1601583906A5086116904 @default.
• W1601583906 hasAuthorship W1601583906A5088301199 @default.
• W1601583906 hasAuthorship W1601583906A5091038323 @default.
• W1601583906 hasBestOaLocation W16015839061 @default.
• W1601583906 hasConcept C166957645 @default.
• W1601583906 hasConcept C191935318 @default.
• W1601583906 hasConcept C2778019345 @default.
• W1601583906 hasConcept C502942594 @default.
• W1601583906 hasConcept C55493867 @default.

• next